TO MEASURE THE EFFECT OF ASPIRIN 300MGS ON PLATELETS IN HEALTHY CONTROLS

To measure the effects of Aspirin loading dose of 300mgs in healthy controls using AA LTA and the Dynamic Platelet Function Assay (DPFA).

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-000499-89-IE

Enrollment

Registered

2015-05-22

Start date

2015-11-09

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease

Interventions

Trade Name: Aspirin 300mgs/Acetysalcyclic acid Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: aspirin CAS Number: 50-78-2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria – Volunteers male or female over the age of 18yrs – Willing and able to give informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 35 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 35

Exclusion criteria

Exclusion criteria: – Unwilling or unable to give informed consent – History of allergies to NSAID or Aspirin – Contraindications to taking aspirin such as peptic ulcer disease, bleeding disorder, haemorrhagic stroke, asthma – Known haematological/platelet disorder – Subject currently taking medication known to affect platelet response including aspirin or P2Y12 inhibitors or has taken them in the last 21 days. – Subject is currently taking analgesics including NSAIDs, cold or sinus remedies or H2 blockers or proton pump inhibitors – Subject is pregnant or breast feeding.

Design outcomes

Primary

Measure	Time frame
Main Objective: To measure the platelet function post aspirin 300mgs.;Secondary Objective: Not appicable;Timepoint(s) of evaluation of this end point: 4-6 hours post administration.; Primary end point(s): • The effect size of LTA platelet aggregation and the dynamic platelet function assay(DPFA) after administration of Aspirin 300mgs. • The variation in platelet response pre and post Aspirin 300mgs using standard LTA and the dynamic assay. • Reliability for measurement of arachidonic acid-induced platelet activity in healthy vounteers and donors on aspirin therapy.	—

Measure

Time frame

Main Objective: To measure the platelet function post aspirin 300mgs.;Secondary Objective: Not appicable;Timepoint(s) of evaluation of this end point: 4-6 hours post administration.; Primary end point(s): • The effect size of LTA platelet aggregation and the dynamic platelet function assay(DPFA) after administration of Aspirin 300mgs. • The variation in platelet response pre and post Aspirin 300mgs using standard LTA and the dynamic assay. • Reliability for measurement of arachidonic acid-induced platelet activity in healthy vounteers and donors on aspirin therapy.

—

Secondary

Measure	Time frame
Secondary end point(s): No;Timepoint(s) of evaluation of this end point: 4-6hrs post administration of aspirin	—

Countries

Ireland

Contacts

Public ContactClinical redearch Centre

Royal College Of Surgeons, Ireland

siobhanmcfadden@rcsi.ie

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026